{"filings":[{"id":1120917,"accession_number":"0001140361-26-025669","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2026-06-18T12:15:34+00:00","items":["8.01","9.01"],"status":"ready","headline":"Grace Therapeutics updates corporate presentation; no specific details available in filing","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed updated corporate presentation as Exhibit 99.1 dated June 17, 2026.","Presentation content not fully included in the filing; unable to assess material changes.","No financial or operational metrics disclosed in the 8-K body."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1120799,"accession_number":"0001140361-26-025667","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2026-06-18T12:01:22+00:00","items":["2.02","9.01"],"status":"ready","headline":"Grace Therapeutics FY2026 net loss $7.8M; FDA CRL for GTx-104; Type A meeting set","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $7.8M ($0.47 loss per share) for FY2026, improved from $9.6M loss in FY2025.","Cash and equivalents $17.0M at March 31, 2026; expected to fund operations at least 12 months.","FDA issued Complete Response Letter for GTx-104 NDA in April 2026; no clinical deficiencies cited; Type A meeting scheduled.","Phase 3 STRIVE-ON trial met primary endpoint; 19% reduction in clinically significant hypotension vs oral nimodipine.","New U.S. patent (No. 12,414,943) for IV dosing regimen extends GTx-104 IP protection to 2043."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":888316,"accession_number":"0001140361-26-024269","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2026-06-05T20:09:22+00:00","items":["5.02","9.01"],"status":"ready","headline":"Grace Therapeutics VP of Clinical Ops departing, will consult at $250/hr for NDA work","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Carrie D'Andrea, VP of Clinical Operations, to cease employment effective June 5, 2026.","She entered a 12-month consulting agreement at $250/hour for clinical development and NDA-related services.","Stock option awards will continue to vest during the consulting term and remain exercisable for 90 days after termination.","Severance benefits per November 2025 letter agreement, conditioned on release of claims and non-compete/non-solicitation covenants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92907,"accession_number":"0001140361-26-016834","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Grace Therapeutics updates corporate presentation in routine 8-K","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an updated corporate presentation as Exhibit 99.1 on April 27, 2026.","No specific financial or operational changes disclosed in the filing.","Presentation content not excerpted; unable to identify new information."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92906,"accession_number":"0001140361-26-016324","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA issues Complete Response Letter for Grace Therapeutics' GTx-104 NDA; cites CMC and non-clinical issues","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CRL for GTx-104 (nimodipine IV) in aSAH; no additional clinical data requested.","Cited leachables data, non-clinical toxicology, and manufacturing deficiencies at CMO.","Company plans Type A meeting with FDA and intends to resubmit after resolving cited items.","STRIVE-ON trial met primary endpoint; 19% reduction in hypotension vs. oral nimodipine.","No deaths deemed drug-related; favorable functional outcomes and higher dose intensity observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104121,"accession_number":"0001140361-26-004927","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Grace Therapeutics reports Q3 FY2026 net loss of $2.3M; cash $18.7M; FDA PDUFA date April 23, 2026 for GTx-104","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.3M ($0.14 per share) improved from $4.2M loss ($0.36 per share) in prior year quarter.","FDA set April 23, 2026 as PDUFA target date for GTx-104 NDA for aSAH treatment.","Cash and equivalents $18.7M as of Dec 31, 2025; company believes sufficient for 12+ months.","Phase 3 STRIVE-ON trial data presented; GTx-104 showed 19% reduction in hypotension vs. oral nimodipine.","Raised $4.0M through warrant exercises at $3.003/share; 1.35M shares issued."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":104120,"accession_number":"0001140361-26-000995","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Grace Therapeutics amends severance for CEO (12-18 mo) and 4 execs (6 mo) as of Jan 10, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Prashant Kohli gets 12 mo base salary (no CIC) or 18 mo base+target bonus (CIC) plus COBRA.","Four other executives get 6 mo base salary (no CIC) or 6 mo base+target bonus (CIC) plus COBRA.","Unvested equity forfeited on termination without Cause absent CIC; fully vests if terminated/resigned within 12 mo after CIC.","Amendments effective January 10, 2026; prior severance terms superseded."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120394,"accession_number":"0001140361-25-041807","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Grace Therapeutics reports Q2 loss of $0.9M; FDA accepts NDA for GTx-104 with PDUFA April 23, 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $0.9M ($0.06 loss per share) vs $3.4M ($0.30 loss) in Q2 last year.","FDA accepted NDA for GTx-104 (nimodipine IV) for aSAH; PDUFA target date April 23, 2026.","U.S. patent issued for IV dosing regimen; IP protection extended to 2043.","Cash $16.9M at Sept 30, 2025; ~$20.0M at Oct 31, 2025 after $4.0M warrant exercises.","R&D expenses fell 80% to $0.6M due to completion of Phase 3 STRIVE-ON trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":120393,"accession_number":"0001140361-25-039020","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Grace Therapeutics secures $4.0M from warrant exercise; GTx-104 PDUFA date set for April 23, 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Secured $4.0M via exercise of 1,345,464 common warrants at $3.003/share from September 2023 private placement.","Remaining 1,190,927 warrants from the same placement expired after FDA accepted GTx-104 NDA for review.","FDA set PDUFA target date of April 23, 2026 for GTx-104 NDA for aneurysmal subarachnoid hemorrhage (aSAH).","GTx-104 is a novel injectable nimodipine formulation for I.V. infusion in aSAH patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136972,"accession_number":"0001140361-25-035337","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2025-09-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Grace Therapeutics receives sixth U.S. patent for GTx-104 dosing regimen; protection extended to 2043","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["US Patent 12,414,943 issued for I.V. nimodipine dosing regimen used in Phase 3 STRIVE-ON trial.","First method-of-use patent for GTx-104; adds to five composition patents expiring 2037.","Patent protection for GTx-104 extended to 2043.","GTx-104 is a clinical-stage injectable nimodipine for aneurysmal subarachnoid hemorrhage (aSAH).","Orphan Drug Designation provides 7 years of marketing exclusivity upon FDA approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136971,"accession_number":"0001140361-25-034845","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2025-09-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Grace Therapeutics shareholders elect 5 directors, approve executive pay and KPMG auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Five director nominees elected: Vimal Kavuru, A. Brian Davis, Prashant Kohli, S. George Kottayil, Edward Neugeboren; votes for ranged 6.29M-6.30M.","Advisory vote on named executive officer compensation passed: 6,178,757 for, 74,002 against, 75,696 abstain, 1,598,490 broker non-votes.","Ratification of KPMG as independent auditor for FY2026 approved: 7,797,832 for, 127,248 against, 1,865 abstain, no broker non-votes.","Approximately 57.32% of outstanding shares (7,926,945 of 13,828,562) were represented at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136970,"accession_number":"0001140361-25-032847","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2025-08-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts Grace Therapeutics' NDA for GTx-104; PDUFA date set for April 23, 2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for GTx-104 (injectable nimodipine) for aSAH treatment; PDUFA target April 23, 2026.","Acceptance triggers up to $7.6M in warrants exercisable at $3.003/share, expiring 60 days post-acceptance or Sept 25, 2028.","Phase 3 STRIVE-ON trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine (28% vs 35%).","GTx-104 showed 54% of patients had ≥95% relative dose intensity vs 8% for oral; 29% more favorable functional outcomes at 90 days.","Orphan Drug Designation provides 7-year US marketing exclusivity if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136969,"accession_number":"0001140361-25-030400","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Grace Therapeutics reports Q1 net loss $3.4M; submits GTx-104 NDA to FDA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.4M ($0.21/sh) vs $2.6M ($0.24/sh) in prior-year quarter; R&D down $1.8M to $0.9M.","Submitted NDA to FDA for GTx-104 (IV nimodipine) for aneurysmal subarachnoid hemorrhage; based on positive STRIVE-ON Phase 3 trial.","STRIVE-ON met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine; 54% patients had ≥95% relative dose intensity.","Cash and equivalents $20.0M; potential warrant exercises of $22.6M ($7.6M + $15.0M) could extend runway into Q2 2027.","Deprioritized GTx-102 and GTx-101 to focus on GTx-104; may license or sell those assets."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154239,"accession_number":"0001140361-25-023557","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2025-06-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Grace Therapeutics submits NDA for GTx-104 in aSAH; Phase 3 data positive","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["NDA for GTx-104 (injectable nimodipine) submitted to FDA for aneurysmal subarachnoid hemorrhage.","Phase 3 STRIVE-ON trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine.","54% of GTx-104 patients had relative dose intensity ≥95% vs 8% on oral; 29% more favorable functional outcomes at 90 days.","Submission may trigger exercise of warrants issued in Sept 2023, yielding up to $7.6M gross proceeds.","GTx-104 has FDA Orphan Drug Designation, providing 7 years U.S. exclusivity if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154238,"accession_number":"0001140361-25-023261","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Grace Therapeutics reports FY2025 net loss of $9.6M; NDA for GTx-104 on track for June 2025 submission","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.6M ($0.79 per share) vs $12.9M ($1.35) in FY2024, decrease driven by change in warrant liabilities.","R&D expenses rose to $9.5M (FY2024: $4.7M) due to the STRIVE-ON Phase 3 trial; cash at $22.1M.","NDA for GTx-104 for aSAH expected to be submitted to FDA by end of June 2025 following positive Type C meeting.","Secured $15M upfront private placement (led by Nantahala Capital, ADAR1 Partners) with potential $15M from warrants.","STRIVE-ON trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine (28% vs 35%)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":154237,"accession_number":"0001140361-25-012944","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Grace Therapeutics announces FDA alignment supporting GTx-104 NDA submission; submission expected Q2 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Primary endpoint met: 19% reduction in clinically significant hypotension (28% GTx-104 vs 35% oral nimodipine).","54% of GTx-104 patients had relative dose intensity ≥95% vs 8% on oral nimodipine.","29% more patients had favorable functional outcomes at 90 days with GTx-104.","8 deaths on GTx-104 vs 4 on oral; none determined drug-related.","NDA submission for GTx-104 anticipated in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172829,"accession_number":"0001140361-25-006659","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2025-03-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Grace Therapeutics updates corporate presentation with cash and runway guidance","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation updated as of March 3, 2025; includes cash position and runway guidance.","No specific financial figures (e.g., cash balance, runway duration) are available in the filing excerpt.","Presentation furnished as Exhibit 99.1; further detail not disclosed in the 8-K text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172828,"accession_number":"0001140361-25-004157","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2025-02-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Grace Therapeutics Q3 net loss $4.2M; Phase 3 STRIVE-ON meets endpoint; $15M placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.2M ($0.36/sh) vs $2.4M ($0.21/sh) YoY; R&D $2.2M up from $1.4M on GTx-104 trial.","Phase 3 STRIVE-ON safety trial met primary endpoint; NDA for GTx-104 anticipated H1 2025.","Secured $15M upfront private placement (Nantahala Capital, ADAR1, Stonepine); up to $15M additional from warrant exercises.","Cash at Dec 31, 2024: $11.1M, down from $23.0M at Mar 31, 2024.","FDA provided guidance on single pivotal trial design for GTx-102 (Ataxia-Telangiectasia) toward NDA."],"consensus_eps_estimate":-0.1887,"consensus_eps_actual":-0.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":172827,"accession_number":"0001140361-25-003645","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Grace Therapeutics: Phase 3 STRIVE-ON trial meets endpoint; announces up to $30M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 STRIVE-ON safety trial met primary endpoint: 19% reduction in clinically significant hypotension vs oral nimodipine; NDA submission expected H1 2025.","Private placement of up to ~$30M gross proceeds ($15M upfront + up to $15M from warrant exercise); led by Nantahala Capital and ADAR1 Partners.","Net proceeds ~$13.8M after fees; expected close Feb 11, 2025; funds for general corporate purposes and GTx-104 pre-commercial development.","54% of GTx-104 patients achieved ≥95% relative dose intensity vs 8% on oral nimodipine; favorable functional outcomes and fewer ICU days observed.","Common warrants exercisable at $3.395/share; expire on earlier of 60 days post-FDA approval or Sep 25, 2028."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189839,"accession_number":"0001140361-24-046314","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Grace Therapeutics reports Q2 net loss $3.4M; Phase 3 STRIVE-ON data due Q1 2025; cash into Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.4M ($0.30 per share) vs $3.3M ($0.43 per share) in prior year; R&D spend up to $3.0M on pivotal trial.","Phase 3 STRIVE-ON safety trial enrollment complete; data readout expected Q1 2025; NDA submission for GTx-104 on track for 1H 2025.","Cash and equivalents $15.1M; projected runway into Q2 2026.","Redomiciled to Delaware and rebranded to Grace Therapeutics; ticker changed to GRCE on Nasdaq.","Hosting KOL event on aSAH on Nov 20, 2024."],"consensus_eps_estimate":-0.2244,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189838,"accession_number":"0001140361-24-044363","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Acasti Pharma changes name to Grace Therapeutics; Nasdaq ticker becomes GRCE","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Name changed from Acasti Pharma Inc. to Grace Therapeutics, Inc., effective Oct 28, 2024.","Nasdaq ticker symbol changed from ACST to GRCE on October 28, 2024.","CUSIP number unchanged at 00439U104; no effect on shareholder rights.","Bylaws amended only to reflect new corporate name; no other changes made."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189837,"accession_number":"0001140361-24-044212","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Acasti Pharma rebrands as Grace Therapeutics; new ticker GRCE effective Oct 28","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company renamed Grace Therapeutics, Inc.; common stock begins trading as GRCE on Nasdaq at market open Oct 28, 2024.","GTx-104 (nimodipine for aSAH) STRIVE-ON trial fully enrolled; data readout expected early 2025, NDA submission H1 2025.","Virtual KOL event on GTx-104 scheduled for Nov 20, 2024 at 2pm ET.","Company completed restructuring, rebuilt management, divested legacy assets, re-domiciled to Delaware.","Addressable U.S. market for GTx-104 estimated at ~$300M; GTx-102 and GTx-101 development deprioritized."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":189836,"accession_number":"0001140361-24-042968","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["1.01","3.03","5.03","9.01"],"status":"ready","headline":"Acasti Pharma redomiciles from Canada to Delaware effective October 7, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Changed jurisdiction from Quebec to British Columbia (Oct 1) and then to Delaware (Oct 7, 2024).","Shareholders approved continuance and domestication at Sept 30, 2024 meeting.","Rights of common stockholders now governed by Delaware General Corporation Law and new Charter/Bylaws.","Entered into indemnification agreements with each executive officer and director.","Common stock continues trading on Nasdaq under symbol ACST."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206351,"accession_number":"0001140361-24-042352","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Acasti Pharma shareholders approve continuance to BC, domestication to Delaware, and 2024 equity plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved continuance from Quebec to British Columbia (5,874,491 For, 71,931 Against, 8,683 Abstain).","Shareholders approved domestication from British Columbia to Delaware (5,891,584 For, 54,366 Against, 9,155 Abstain).","Shareholders approved the 2024 Equity Incentive Plan (5,832,903 For, 86,289 Against, 35,913 Abstain).","All five director nominees were elected; KPMG ratified as auditor (7,055,362 For).","Advisory vote on named executive officer compensation passed (5,685,429 For, 98,138 Against)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206350,"accession_number":"0001140361-24-041832","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-09-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Acasti Pharma completes enrollment in pivotal Phase 3 STRIVE-ON trial of GTX-104 for aSAH","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Patient enrollment completed for GTX-104 (injectable nimodipine) vs oral nimodipine in 100 patients across ~25 U.S. hospitals.","Data readout from STRIVE-ON safety trial expected early calendar 2025; primary endpoint is comparative adverse events including hypotension.","NDA submission to FDA on track for first half of 2025, consistent with timeline.","CEO Prashant Kohli says milestone achieved ahead of original expectations; believes GTX-104 may transform aSAH standard of care."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206349,"accession_number":"0000950170-24-098049","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-08-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Acasti Pharma enters new employment agreement with CEO Prashant Kohli","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual base salary of $500,000 and eligible for discretionary bonus up to 50% of base.","Severance of 12 months' base salary if terminated without cause (including after change of control).","Subject to board approval, may receive stock options under the company's equity incentive plan.","12-month non-compete and non-solicitation clauses; standard benefits and vacation included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":206348,"accession_number":"0000950170-24-094359","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acasti Pharma Q1 FY2025 net loss $2.6M; STRIVE-ON trial enrollment exceeds 50%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.6M ($0.24 loss per share) vs $4.0M ($0.54) in prior-year quarter.","Cash and equivalents $19.4M as of June 30, 2024; projected runway into Q2 2026.","Pivotal Phase 3 STRIVE-ON safety trial surpassed 50% enrollment; completion expected late 2024 to early 2025.","NDA submission to FDA for GTX-104 anticipated in first half of calendar 2025.","R&D expenses rose to $2.7M from $1.1M, driven by GTX-104 clinical activities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223458,"accession_number":"0000950170-24-078447","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Acasti achieves >50% enrollment in pivotal Phase 3 STRIVE-ON safety trial for GTX-104","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 3 STRIVE-ON trial of GTX-104 (IV nimodipine) for aneurysmal subarachnoid hemorrhage (aSAH) surpassed 50% patient enrollment.","Trial design: 100 patients, open-label, randomized 1:1 vs oral nimodipine; primary endpoint is comparative safety (hypotension).","Enrollment began Oct 2023; completion anticipated late 2024–early 2025; NDA submission on track for 1H 2025.","GTX-104 is designed for IV infusion in ICU, avoiding nasogastric tube in unconscious/dysphagic aSAH patients.","US addressable market for GTX-104 estimated at ~$300M per market research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223457,"accession_number":"0000950170-24-075880","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acasti Pharma FY2024 net loss $12.9M; STRIVE-ON trial on track for NDA in H1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 net loss $12.9M ($1.35 per share), down from $42.4M in FY2023; decrease due to prior year impairments not recurring and restructuring.","R&D expenses fell to $4.7M from $10.0M; G&A expenses down to $6.4M from $7.6M reflecting strategic realignment toward GTX-104.","Cash and equivalents $23.0M as of March 31, 2024; projected runway into Q2 2026.","STRIVE-ON Phase 3 safety trial enrollment on track; potential NDA submission to FDA in first half of 2025.","Completed $7.5M private placement in September 2023; deprioritized GTX-102 and GTX-101 to focus on GTX-104."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":223456,"accession_number":"0000950170-24-038882","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Acasti Pharma updates corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation dated April 1, 2024, furnished as Exhibit 99.1.","Presentation covers company overview and NASDAQ listing (ACST).","No financial results, guidance, or operational milestones were announced.","Presentation is available for investor reference on the company's IR page."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242902,"accession_number":"0000950170-24-013568","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acasti Pharma Q3 FY2024 net loss narrows to $2.4M; cash runway extends to early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.4M ($0.21/share) vs $3.9M ($0.52) in prior-year quarter.","R&D expenses decreased 44% YoY to $1.4M due to resource prioritization on GTX-104.","Cash, equivalents and ST investments $25.1M; runway extended into 2nd calendar Q 2026.","Pivotal STRIVE-ON Phase 3 trial enrollment ongoing; NDA submission on track for 1H 2025.","Company secured $7.5M private placement in prior quarter to bolster balance sheet."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":242901,"accession_number":"0000950170-24-002689","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Acasti Pharma appoints Robert J. DelAversano as principal financial and accounting officer, effective Jan 5, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert J. DelAversano, 52, CPA and former VP Finance, becomes principal financial and accounting officer.","Brian Ford removed as interim-CFO; remains as financial consultant on an as-needed basis.","DelAversano receives $290,000 base salary, up to 30% target bonus, and 42,000 stock options at $2.125 per share.","DelAversano joined Acasti in Nov 2023; prior experience at OncoSec and Brio Financial Group."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260268,"accession_number":"0000950170-23-070574","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-12-15T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Acasti Pharma dismisses Ernst & Young, engages KPMG as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved dismissal of E&Y as independent auditor on Dec 11, 2023; E&Y letter filed as Exhibit 16.1.","KPMG engaged as new independent auditor for fiscal year ending Mar 31, 2024, effective same date.","No disagreements or reportable events with E&Y during fiscal 2023 or subsequent interim period.","Decision based on KPMG's US location, competitive review, and other business factors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260267,"accession_number":"0000950170-23-062474","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acasti Q2 FY2024 net loss falls to $3.3M; first patient dosed in pivotal GTX-104 trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.3M ($0.43/share) vs $5.0M ($0.66/share) in Q2 FY2023; R&D spending cut to $0.4M.","Cash and cash equivalents $27.0M at Sep 30, 2023, down $0.9M from Mar 31, 2023; $7.5M private placement closed in Sep 2023.","First patient enrolled in STRIVE-ON Phase 3 trial of GTX-104 for aneurysmal subarachnoid hemorrhage (aSAH).","GTX-104 NDA submission to FDA on track for first half of 2025.","Private placement led by ADAR1 Partners; proceeds to fund Phase 3 trial, NDA prep, and working capital."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260266,"accession_number":"0000950170-23-054637","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-10-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Acasti Pharma Settles CaPre Dispute with Aker BioMarine and Doses First Patient in GTX-104 Trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acasti entered a Settlement Agreement with Aker BioMarine to resolve a $2.6 million dispute over a supply agreement for CaPre raw material.","Under the settlement, Aker BioMarine retains ownership of all raw krill oil, production equipment, and CaPre-related intellectual property.","Acasti announced dosing of first patient in the pivotal Phase 3 STRIVE-ON safety trial for GTX-104 in aSAH.","The STRIVE-ON trial aims to support a potential NDA submission anticipated in the first half of calendar 2025.","Acasti extended its projected cash runway to the first calendar quarter of 2026 following a $7.5 million private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":260265,"accession_number":"0000950170-23-052891","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-10-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Acasti Pharma shareholders elect directors, ratify auditor, approve exec comp at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Five director nominees elected with >97% votes for each; non-votes ~1.27M.","Ernst & Young LLP appointed as auditor with 97.65% votes for (3,982,999 for).","Advisory vote on executive compensation approved with 97.24% votes for (2,730,102 for).","Shareholder turnout 54.76% (4,078,661 votes of 7,448,033 outstanding shares).","Meeting held Oct 10, 2023; proxy solicitation unopposed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277563,"accession_number":"0000950170-23-049796","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-09-26T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Acasti Pharma closes $7.5M private placement for GTX-104 development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement on Sept 25, 2023: 1.95M common shares at $1.848 each, pre-funded warrants for 2.11M shares, and common warrants for 2.54M shares at $3.003 exercise.","Gross proceeds ~$7.5M, net ~$7.3M after fees; related parties (Shore Pharma, SS Pharma) participated.","Proceeds intended for GTX-104 Phase 3 trial, pre-commercial planning, working capital, and general corporate purposes.","Common warrants expire on the earlier of 60 days after FDA NDA acceptance for GTX-104 or 5 years from issuance.","Company to file resale registration statement within 30 days; failure may trigger liquidated damages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277562,"accession_number":"0000950170-23-041606","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acasti Pharma Q1 net loss $4.0M; FDA aligned on Phase 3 GTX-104 trial; cash runway to Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $4.0M ($0.54 per share) vs $4.5M ($0.61 per share) year ago.","Cash and equivalents $21.6M at quarter end; projected runway through Q2 2025 covering potential GTX-104 NDA submission.","FDA alignment on STRIVE-ON Phase 3 safety trial for GTX-104; first patient dosing expected Q4 2023.","R&D expenses fell to $1.1M from $2.3M on restructuring; $1.5M severance costs incurred.","Appointed new CMO, VP Clinical Operations, VP Program Management; expanded Scientific Advisory Board with three key opinion leaders."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277561,"accession_number":"0000950170-23-034113","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-07-24T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Acasti Pharma regains Nasdaq minimum bid price compliance after reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 24, 2023 confirming compliance with Listing Rule 5550(a)(2).","Compliance achieved through a 1-for-6 reverse share split effective July 10, 2023.","Company continues trading on Nasdaq Capital Market under symbol ACST."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277560,"accession_number":"0000950170-23-032154","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-07-07T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Acasti Pharma announces 1-for-6 reverse stock split to regain Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-6 effective July 10, 2023; shares trade on split-adjusted basis from market open.","Outstanding shares reduced from ~44.6M to ~7.4M; no fractional shares issued, rounded up to whole share.","Split intended to regain compliance with Nasdaq $1.00 minimum bid price continued listing requirement.","New CUSIP number is 00430K865; trading symbol remains ACST.","Transfer agent Computershare will handle exchanges; street-name holders need not take action."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":277559,"accession_number":"0000950170-23-031612","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-07-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Acasti aligns with FDA on GTX-104 Phase 3 safety trial protocol; STRIVE-ON to start Q4 2023","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA confirmed alignment on STRIVE-ON trial design and dosing regimen for GTX-104 in aSAH patients.","STRIVE-ON will enroll ~100 patients at ~25 US hospitals; primary endpoint is safety vs oral nimodipine.","GTX-104 administered to >150 healthy volunteers with comparable safety to oral nimodipine to date.","Cash runway projected through potential NDA submission in H1 2025.","First patient dosing expected in Q4 2023; NDA submission targeted for first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295520,"accession_number":"0000950170-23-029500","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Acasti Pharma reports FY2023 net loss of $42.4M, focuses on GTX-104 Phase 3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $42.4M ($0.95 loss per share) vs $9.8M loss prior year; impairments of $33.5M.","Cash, cash equivalents and short-term investments $27.9M, expected to fund through Q2 2025 for potential NDA filing.","FDA confirmed 505(b)(2) pathway for GTX-104; Phase 3 Safety Study protocol submitted, first patient H2 2023.","Strategic realignment: R&D focus solely on GTX-104, evaluating partnerships for GTX-102/GTX-101.","R&D expenses $9.9M (up 77% YoY); G&A expenses reduced to $7.6M; restructuring with layoffs in Canada."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295519,"accession_number":"0000950170-23-021346","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Acasti Pharma appoints new CMO, VP Clinical Ops; terminates CFO and COOs; submits GTX-104 Phase 3 plan to FDA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Appointed Dr. R. Loch Macdonald as CMO, Carrie D'Andrea as VP Clinical Ops, Amresh Kumar as VP Program Mgmt; effective immediately or May 15.","Terminated CFO Brian Ford (interim until June 30), COO Canada Pierre Lemieux, COO US George Kottayil; severance payments.","Submitted full protocol for GTX-104 pivotal Phase 3 Safety Study to FDA; first patient dosing expected Q4 2023.","Strategic realignment focuses on GTX-104; cash runway extended through Q2 2025; evaluating alternatives for GTX-102, GTX-101.","Discontinuing Canadian operations, laying off substantially all workforce; rebuilding leaner US organization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":295518,"accession_number":"0000950170-23-011938","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-04-05T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Acasti appoints Prashant Kohli as CEO; FDA allows Phase 3 safety study for GTX-104 to proceed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Prashant Kohli appointed CEO effective April 4, 2023, succeeding Jan D'Alvise who mutually agreed to depart.","FDA Type C meeting response: concurred with 505(b)(2) pathway for GTX-104; Phase 3 safety study can proceed pending final protocol approval.","Phase 3 trial: 1:1 randomized vs oral nimodipine in aSAH patients at 25-30 US sites; primary endpoint is safety (hypotension adverse events).","First patient enrollment expected in H2 2023; if primary endpoint met, NDA filing under 505(b)(2) expected to follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316068,"accession_number":"0000950170-23-011424","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director John Canan resigns from Acasti Pharma board, no dispute","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jean-Marie (John) Canan resigned from the board effective March 30, 2023.","Canan was a member of the audit committee and governance and human resources committee.","Resignation was not due to any dispute or disagreement with the Company or board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":316067,"accession_number":"0000950170-23-007448","cik":1444192,"company_name":"Grace Therapeutics, Inc.","ticker":"GRCE","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Acasti voluntarily delists from TSX Venture; confirms no SVB/Silvergate exposure","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Voluntary delisting from TSXV effective March 27, 2023; Nasdaq listing under ACST unaffected.","Company cites low TSXV volume and high dual-listing costs; expects central Nasdaq marketplace to aid liquidity.","Confirms no exposure to Silicon Valley Bank or Silvergate Bank; no deposits held at those institutions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":37292403.094420604,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}